Child and Adolescent Psychiatric Clinics of North America
Attention Deficit Hyperactivity Disorder in Preschool Children
Section snippets
Prevalence of preschool-onset attention deficit hyperactivity disorder
Early onset of ADHD symptoms and associated impairment has been reported in community and clinical samples [9], [10]. Although initial ADHD symptoms may be noticed as early as 3 years of age [11], [12], the most common age of full ADHD diagnosis does not occur until 7 to 10 years of age [13]. Epidemiologic surveys of community samples have reported that 2% to 6% of preschoolers met full criteria for ADHD [12], [14], [15], somewhat lower than the worldwide 5.7% prevalence rates reported for ADHD
Diagnostic validity
The validity of an ADHD diagnosis in the preschool years has often been questioned. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) does not provide specific, developmentally adjusted ADHD criteria that apply to preschoolers. Rather, the same diagnostic criteria are applied to patients across the lifespan. The frequent use of pharmacotherapy in treating preschoolers, however, makes determining a valid diagnosis at this young age important [21]. Consequently,
Impairment with attention deficit hyperactivity disorder
Current DSM-IV diagnostic criteria for ADHD require demonstration of impairment in a minimum of two settings [25]. Symptoms of ADHD in preschoolers produce significant impairment in a multitude of settings, including home, school, and during social functioning, even to the degree of impacting the child's safety [6], [20], [26]. Compared with same-aged controls, preschoolers who have ADHD are more often suspended from preschool or daycare (15% versus 0.8%) because of disruptive behavior (7.8%
Comorbidities
Just as with older children, preschool ADHD frequently co-occurs with other psychiatric disorders [31]. Young children who have ADHD have been shown to have increased rates of developmental delays and developmental coordination disorder [32]. Of preschoolers who had ADHD, 22% also had a language disorder [33]. High rates of language problems have also been reported in other preschool ADHD samples [7], along with underachievement in reading and math [6]. Like their school-aged counterparts,
Persistence of attention deficit hyperactivity disorder symptoms with preschool presentation
Longitudinal studies report that preschool-onset ADHD symptoms may persist over time [6], [21], [40]. ADHD symptoms identified in 3-year-olds remained in 50% of those children by 6 years of age, and 48% by 9 years of age [11], and the same children were more likely to meet diagnostic criteria at 13 years of age than comparisons [40].
Nearly all of the 255 4- to 6-year-olds who had ADHD followed up for 3 years by Lahey and colleagues [21] continued to meet criteria for one subtype of ADHD,
Use of methylphenidate in children younger than 6 years who have attention deficit hyperactivity disorder
Despite a U.S. Food and Drug Administration (FDA) warning against its use in children younger than 6 years, methylphenidate has frequently been prescribed off-label for treating ADHD symptoms in preschoolers. As early as 1990, 34% of pediatricians and 15% of family practitioners reported prescribing stimulant medications to preschoolers who had ADHD [42]. This off-label use of methylphenidate increased between 1990 and 1995 [43], with a 49% increase between 2000 and 2003 for ADHD in children
Summary
Preschool ADHD is an impairing behavioral disorder, and it co-occurs with other serious psychiatric disorders. Early identification of ADHD and intervention may potentially minimize or prevent adverse outcomes and future pathology. Although data from studies of school-aged children have guided the use of stimulants in preschoolers, the limited safety and efficacy information on the short- and long-term effects of these medications in young children makes initiating pharmacotherapy a difficult
References (94)
- et al.
Correlates of mental health service utilization and unmet need among a sample of male adolescents
Addict Behav
(2001) - et al.
Validity of DSM-IV attention-deficit/hyperactivity disorder for younger children
J Am Acad Child Adolesc Psychiatry
(1998) - et al.
Help-seeking for behavior problems by parents of preschool children: a community study
J Am Acad Child Adolesc Psychiatry
(1996) - et al.
Validity of the age-of-onset criterion for ADHD: a report from the DSM-IV field trials
J Am Acad Child Adolesc Psychiatry
(1997) - et al.
Prevalence rates and correlates of psychiatric disorders among preschool children
J Am Acad Child Adolesc Psychiatry
(1996) - et al.
NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale
J Am Acad Child Adolesc Psychiatry
(1995) - et al.
Stimulant treatment for children: a community perspective
J Am Acad Child Adolesc Psychiatry
(2000) - et al.
Preschool children with attention-deficit/hyperactivity disorder: impairments in behavioral, social, and school functioning
J Am Acad Child Adolesc Psychiatry
(2001) - et al.
Psychiatric comorbidity and functioning in clinically referred preschool children and school-age youths with ADHD
J Am Acad Child Adolesc Psychiatry
(2002) - et al.
Disruptive behavior in young children: what does it mean?
J Am Acad Child Adolesc Psychiatry
(2001)
Psychiatric diagnosis in preschool children
J Am Acad Child Adolesc Psychiatry
Correlates of comorbid psychopathology in children with ADHD
J Am Acad Child Adolesc Psychiatry
The effects of methylphenidate on the interactions of preschool ADHD children with their mothers
J Am Acad Child Adolesc Psychiatry
Effects of methylphenidate on preschool children with ADHD: cognitive and behavioral functions
J Am Acad Child Adolesc Psychiatry
Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD
J Am Acad Child Adolesc Psychiatry
A prospective study of stimulant response in preschool children: insights from ROC analyses
J Am Acad Child Adolesc Psychiatry
Rationale, design, and methods of the Preschool ADHD Treatment Study (PATS)
J Am Acad Child Adolesc Psychiatry
Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD
J Am Acad Child Adolesc Psychiatry
Safety and tolerability of methylphenidate in preschool children with ADHD
J Am Acad Child Adolesc Psychiatry
Stimulant-related reductions of growth rates in the PATS
J Am Acad Child Adolesc Psychiatry
Growth rebound after termination of stimulant drugs
J Pediatr
Parent-based therapies for preschool attention-deficit/hyperactivity disorder: a randomized, controlled trial with a community sample
J Am Acad Child Adolesc Psychiatry
Reduction of attention deficit and internalizing symptoms in preschoolers through parent-child interaction training
J Am Acad Child Adolesc Psychiatry
Does maternal ADHD reduce the effectiveness of parent training for preschool children's ADHD?
J Am Acad Child Adolesc Psychiatry
Follow-up one year after parent-child interaction training: effects on behavior of preschool children
J Am Acad Child Adolesc Psychiatry
Children in special education programs: attention deficit hyperactivity disorder, use of services, and unmet needs
Am J Public Health
Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder
JAMA
Increasing identification of psychosocial problems: 1979–1996
Pediatrics
Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey
Arch Pediatr Adolesc Med
Diagnosis of attention-deficit/hyperactivity disorder and use of psychotropic medication in very young children
Arch Pediatr Adolesc Med
The emergence of attention deficits in early childhood: a prospective study
J Dev Behav Pediatr
Follow-up of hard-to-manage preschoolers: adjustment at age 9 and predictors of continuing symptoms
J Child Psychol Psychiatry
More than the terrible twos: the nature and severity of behavior problems in clinic-referred preschool children
J Abnorm Child Psychol
How common is attention-deficit/hyperactivity disorder? Towards resolution of the controversy: results from a population-based study
Acta Paediatr Suppl
The Great Smoky Mountains Study of Youth. Goals, design, methods, and the prevalence of DSM-III-R disorders
Arch Gen Psychiatry
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Am J Psychiatry
The preschool age psychiatric assessment (PAPA): a structured parent interview for diagnosing psychiatric disorders in preschool children
Patterns of psychopathology and dysfunction in clinically referred preschoolers
J Dev Behav Pediatr
Three-year predictive validity of DSM-IV attention deficit hyperactivity disorder in children diagnosed at 4-6 years of age
Am J Psychiatry
Factor structure of parent- and teacher-rated ADHD symptoms in preschoolers in the preschoolers with ADHD treatment study (PATS)
J Child Adolesc Psychopharmacol
Maternal report of attention deficit hyperactivity disorder symptoms in preschool children
Child Care Health Dev
DSM-IV field trials for attention deficit hyperactivity disorder in children and adolescents
Am J Psychiatry
Diagnostic and statistical manual of mental disorders. 4th edition. [text revision]
Preschool psychopathlogy: lessons for the lifespan
Journal of Child Psychology and Psychiatry
Injuries to children with attention deficit hyperactivity disorder
Pediatrics
Risk for injury in preschoolers: relationship to attention deficit hyperactivity disorder
Child Neuropsychol
Unintentional injury in preschool boys with and without early onset of disruptive behavior
J Pediatr Psychol
Cited by (0)
Dr. Greenhill has received support from Celltech, Cephalon, Eli Lilly, Janssen, McNeil, Medeva, Novartis Corporation, Noven, Otsuka, Pfizer, Sanofi, Shire, Solvay, Somerset, and Thompson Advanced Therapeutics Communications. As part of an effort to help execute the FDA suicidality classification mandates, Dr. Posner has received funding from the FDA to develop and implement the suicidality classification system used in their child antidepressant safety analyses. This system was subsequently used in the adult antidepressant safety analyses. As part of an effort to help execute the FDA suicidality classification mandates, Dr. Posner has had research support from Abbott, Bristol Myers Squibb, Organon, Schwarz, GlaxoSmithKline, Eli Lilly, Johnson and Johnson, Wyeth Research, Sanofi-Aventis, Cephalon, Novartis, Shire Pharmaceuticals, Merck, Pfizer and Vivus. Dr. Kratochvil has received support from Cephalon, Eli Lilly, McNeil, Abbott, Pfizer, Shire, Somerset, and AstraZeneca.